Baseline characteristics
| 24-Week placebo-controlled treatment period | All Bari-RA | |||
|---|---|---|---|---|
| Characteristic | Placebo(N=1070) | Baricitinib 4 mg(N=997) | Baricitinib 2 mg(N=479) | And Bari dose (N=3492) |
| Age, years, mean (SD) | 52.9 (11.9) | 53.7 (12.0) | 53.2 (12.0) | 52.9 (12.2) |
| Female, n (%) | 862 (80.6) | 794 (79.6) | 386 (80.6) | 2760 (79.0) |
| Duration of RA*, years, mean (SD) | 8.9 (8.4) | 8.9 (8.6) | 9.0 (8.1) | 7.7 (8.2) |
| Region, n (%) | ||||
| USA/Canada | 240 (22.4) | 225 (22.6) | 162 (33.8) | 840 (24.1) |
| Central/South America and Mexico | 203 (19.0) | 197 (19.8) | 54 (11.3) | 701 (20.1) |
| Asia (excluding Japan) | 84 (7.9) | 83 (8.3) | 38 (7.9) | 226 (6.5) |
| Japan | 156 (14.6) | 132 (13.2) | 36 (7.5) | 514 (14.7) |
| European Union | 263 (24.6) | 246 (24.7) | 125 (26.1) | 783 (22.4) |
| Rest of the world | 124 (11.6) | 114 (11.4) | 64 (13.4) | 428 (12.3) |
| Background MTX use, yes, n (%) | 967 (90.4) | 903 (90.6) | 386 (80.6) | 2661 (76.2) |
| Corticosteroid use, yes, n (%) | 610 (57.0) | 538 (54.0) | 246 (51.4) | 1754 (50.2) |
| Mean neutrophil count (×109 cells/L) | 5.83 | 6.04 | 5.73 | NA |
| Mean lymphocyte count (×109 cells/L) | 1.82 | 1.84 | 1.87 | NA |
| Mean platelet count (×109 cells/L) | 289 | 293 | 284 | NA |
*Time from RA diagnosis.
Bari, baricitinib; MTX, methotrexate; NA, not available; RA, rheumatoid arthritis.